H
UMAN interferon-~ (IFN-~) has been administered intravenously, intrathecally, or intratumorally to patients with recurrent gliomas by several Japanese investigators. J 0-~ 2 J 5.~ 7 Responses were noted by Sano, et al, in 12 of 54 patients treated intravenously (unpublished data) and by Nagai and Arai ~~ in eight of 20 patients treated intrathecally or intratumorally. Other authors have treated smaller groups of patients with less impressive responses. ~-3, 22 Our experience with interferon has included responses in seven of 17 patients with recurrent gliomas treated with human interferon-a s and response in one of 14 patients treated with recombinant interferon--y. 7 We have evaluated recombinant IFN-/3 for treatment of patients with recurrent gliomas, and the lack of response obtained in the seven patients studied is described in this brief report.
Clinical Material and Methods
This study was designed to evaluate toxicity and possible efficacy of recombinant IFN-/L We used IFN~ser (Betaseron), a genetically altered, recombinant human interferon in which serine has been substituted for the cysteine residue normally found at position 17 of the IFN-/3 molecule. The resulting molecule exhibits a specific activity similar to that of native IFN-/3, and in vitro studies have shown that the biological properties of the two molecules are remarkably similar. In this series, |FN-/Jser was administered systemically to adult patients with recurrent, progressive gliomas. The characteristics of these patients are listed in Table 1 . The mean age was 49 years (range 35 to 67 years), the mean Karnofsky rating was 74 (range 60 to 90), and the mean tumor volume was 36 cu cm (range 9 to 78 cu cm). Six of the seven patients had glioblastoma multiforme and one had a recurrent astrocytoma. Each patient had previously undergone subtotal resection of the tumor followed by radiotherapy (plus BCNU (1,3-bis(2-chloroethyl)-l-nitrosourea) chemotherapy in two) and now presented with computerized tomography (CT) evidence of progressing tumor.
The dose schedule for IFN-/3~r was begun at 90 x 106 IU intravenously on Monday, Wednesday, and Friday for 2 weeks to complete one cycle. The dose was then escalated to the next level at the beginning of each 247/282 (36-533+) CT responders/stable/progression 0/3/4 * GBM = glioblastoma multiforme; TTP = time to tumor progression; CT = computerized tomography. (Table 2) . Dose escalation was continued based on each patient's tolerance for the drug. For patients who experienced defined Grade III/ IV toxicity (Table 3) , the escalation phase was terminated and the patient continued therapy at a maintenance level, which we arbitrarily defined as one dose level below the dose at which the toxicities were experienced. The maintenance phase continued as long as the patient remained stable as judged by CT scanning and did not suffer defined Grade III/IV toxicity. Baseline evaluations prior to beginning treatment included contrast-enhanced CT, neurological examination, chest x-ray film, Karnofsky functional rating, electrocardiogram, urinalysis, and blood studies for hematological, hepatic, and renal status. Each patient was followed with serial, monthly, contrast-enhanced CT scans, Karnofsky performance status testing, and neurological examinations. Blood and urine studies were repeated every 1 to 2 months throughout the treatment course.
Efficacy was determined by comparing the baseline neurological examination and tumor volumes from contrast-enhanced CT scans to subsequent serial evaluations. Clinical response was defined as an improvement in the results of neurological examination and/or a 25 % or greater reduction in enhancing tumor volume in the absence of any increase in steroids. Stable disease consisted of no change as determined by neurological examination or less than a 25% change in tumor volume calculated from enhanced CT scan. Progression of disease was defined as a deterioration in neurological examination and/or a 25% or greater increase in tumor volume demonstrated by CT scanning in the absence of a reduction in steroids. Times to disease progression and overall survival times were determined from the initiation of IFN-~eT therapy.
Results
The patients received total cumulative doses of IFN-/3~r ranging from 1440 to 11,340 x 106 IU (mean 5001 x 106 IU) administered for periods from 35 to 12 weeks. Based upon the CT scan and neurological examination at 8 weeks after beginning treatment, no patient responded, three remained stable (for 56 to 436 days), and four had disease progression during that time (Table 1). Median time to disease progression in the seven patients was 44 days (range 25 to 408 days) and median survival time was 282 days (range 36 to 533+ days). As of November 30, 1988, one patient is alive but not being treated with interferon at this time because of toxicity.
All seven patients experienced some degree of mild toxicity on the day of treatment, consisting of fever, chills, and myalgias. Acetaminophen and ibuprofen minimized these symptoms at subsequent treatments. One patient experienced mild nausea and vomiting on the day of treatment which responded to prochlorperazine.
Severe toxicity requiring a change in dose and/or cessation of treatment is listed in Table 3 and was experienced by five of the patients. Extreme fatigue was experienced by all five of these patients. In addition, one of the five patients experienced increasingly severe myalgias. Another patient experienced mental confusion and also developed a paralytic ileus, pneumonia, and septicemia in the absence of significant granulocytopenia; these medical problems resolved and treatment was resumed, but the patient again experienced mental confusion on a lower dose and treatment was stopped. One patient experienced a persistent decreased platelet count. In addition, this patient developed diabetes mellitus unrelated to any change in steroid use, which required high doses of insulin for management; this problem was successfully regulated only after interferon therapy ceased. He later developed a deep vein thrombosis requiring anticoagulant therapy; he continued to deteriorate medically, and died as a result of pneumonia and sepsis. During treatment at the maximum dose level, another patient experienced an acute hemorrhage into the tumor, requiring surgical intervention with uneventful recovery.
Discussion
Interferon-C/has been shown to inhibit replication of human glioma cells in vit? 'O 5"65~'19"2~ and in nude mice in vivo. 13"14"16"18 In vitro exposure of human glioma cells to the liposome-entrapped human IFN-/3 resulted in increased cytotoxicity compared to free interferon. 4 Clinical treatments for recurrent glioma using intravenous, intrathecal, or intratumoral routes of administration were first conducted in Japan. 22 with smaller groups of patients revealed somewhat less impressive response rates. Our own experience in this small series with recombinant IFN-fl administered systemically was disappointing, with no CT scan evidence of response and only three instances of temporary stabilization of the CT scan appearance. The more recent report by Yoshida, et aL, "-z of four complete responses and one partial response in nine patients with recently diagnosed brain tumors when treated with the combination of radiotherapy, ACNU (l-(4-amino-2-methyl-5-pyrimidinyl)-methyl-3-(2-chloroethyl)-3-nitrosourea), and IFN-/~ is certainly of interest and illustrates the need to evaluate further the role the various interferons may play in the treatment of brain-tumor patients, either as part of initial management or at the time of previous treatment failure. In view of the modest results with IFN-/3~cr alone, the report by Yoshida, et al., further emphasizes the need to determine the possible synergistic therapeutic effects of IFN-r and conventional chemotherapeutic agents.
